Tackling the undruggable: How Beactica's protein degradation platform might transform glioblastoma treatment

In this episode of BioBiz Buzz, CEO and co-founder Per Källblad discusses with co-host Mike Ward how the company's dual-modality strategy addresses the fundamental limitations of traditional small molecule inhibitors, particularly for proteins lacking well-defined binding pockets or serving complex scaffolding functions. 

The conversation explores Beactica's lead programme BEA-17, a first-in-class LSD1-CoREST degrader that has received FDA Orphan Drug Designation for glioblastoma, a devastating cancer where median survival remains just 12-18 months. By degrading the entire LSD1-CoREST complex rather than merely inhibiting it, BEA-17 simultaneously restores antigen presentation, induces viral mimicry responses, and reprograms the tumour microenvironment to enable immune recognition. 

Källblad also discusses the company's TEAD degrader programme P65-047, which shows superior efficacy through its unique ability to eliminate resistance-mediating co-factors like VGLL3, and outlines Beactica's biomarker-driven clinical development strategy designed to maximize patient selection precision as the company advances toward Phase I trials.

See all recent coverage